Jeffrey Bluestone net worth and biography

Jeffrey Bluestone Biography and Net Worth

Director of Gilead Sciences

Dr. Bluestone joined our Board in December 2020. Dr. Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell therapies to treat serious autoimmune and inflammatory diseases. He has held this role since 2019. From 2015 to 2019, he led the Parker Institute for Cancer Immunotherapy as President and Chief Executive Officer. Dr. Bluestone is the A.W. and Mary Margaret Clausen Distinguished Professor Emeritus in the Diabetes Center at University of California San Francisco, where he has been a member of the faculty and served in various other roles for over 20 years, including the Director of the Diabetes Center from 2000 to 2019. He is an international leader in the field of immunotherapy and has published more than 500 papers over nearly four decades focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development of multiple immunotherapies, including the first medicine approved by the U.S. Food and Drug Administration (FDA) to delay/prevent autoimmune Type 1 diabetes and the first FDA-approved checkpoint inhibitor for the treatment of metastatic melanoma and other cancers. Dr. Bluestone was the founding director of the Immune Tolerance Network, the largest National Institutes of Health-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity and asthma/allergy. He served as a member of the Blue Ribbon Panel, appointed by then Vice President Joe Biden, as a member of the National Cancer Moonshot Task Force. Dr. Bluestone is a member of the National Academy of Medicine and American Academy of Arts and Sciences, was a recipient of the prestigious Guggenheim Fellowship, and previously served as the Ludwig Professor and Director of the Ben May Institute at the University of Chicago. He previously served on the board of directors of Provention Bio, Inc. from 2013 to 2022.

What is Jeffrey Bluestone's net worth?: The estimated net worth of Jeffrey Bluestone is at least $974,688.40 as of November 26th, 2024. Dr. Bluestone owns 8,920 shares of Gilead Sciences stock worth more than $974,688 as of March 27th. This net worth estimate does not reflect any other assets that Dr. Bluestone may own. Learn More about Jeffrey Bluestone's net worth.
How do I contact Jeffrey Bluestone?: The corporate mailing address for Dr. Bluestone and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at investor_relations@gilead.com. Learn More on Jeffrey Bluestone's contact information.
Has Jeffrey Bluestone been buying or selling shares of Gilead Sciences?: Jeffrey Bluestone has not been actively trading shares of Gilead Sciences during the last quarter. Most recently, Jeffrey Bluestone sold 6,788 shares of the business's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a transaction totalling $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares of the company's stock, valued at $815,198.80. Learn More on Jeffrey Bluestone's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Jeffrey Bluestone (Director), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 797,366 shares worth more than $75,721,855.55. The most recent insider tranaction occured on March, 10th when CFO Andrew D Dickinson sold 17,929 shares worth more than $2,118,669.93. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 3/10/2025.

Jeffrey Bluestone Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/26/2024	Sell	6,788	$91.39	$620,355.32	8,920

Jeffrey Bluestone Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $109.27

$107.90

$110.46

50 Day Range

MA: $104.69

$91.65

$117.41

2 Week Range

Now: $109.27

$62.07

$119.96

Volume

7,391,019 shs

Average Volume

6,785,008 shs

Market Capitalization

$136.08 billion

P/E Ratio

295.32

Dividend Yield

2.98%

Beta

0.21